Featured Research

from universities, journals, and other organizations

Cancer Study Finds Adolescents Don't Get Same Access To Latest Treatments As Younger Patients

Date:
January 16, 2008
Source:
Children's Hospital of Pittsburgh
Summary:
The overall survival rate from cancer now is lower in older adolescents and young adults with cancer than in younger children, in part because of a lack of access to clinical trials nationally for the older age group, according to a new study.

The overall survival rate from cancer now is lower in older adolescents and young adults with cancer than in younger children, in part because of a lack of access to clinical trials nationally for the older age group, according to a study by pediatric oncologists at Children's Hospital of Pittsburgh of UPMC.

Nationally, cure rates in children younger than 15 with cancer have improved dramatically over the last 30 years, increasing from 60 percent to approximately 85 percent at five years from the time of diagnosis. In contrast, similar improvements in survival rates have not been seen in adolescents and young adults ages 15--22, with cure rates remaining steady at approximately 70 percent throughout the same time period.

This can be attributed to the fact that adolescents and young adults don't have the same access to cutting-edge cancer treatments provided though clinical trials, according to the study led by Peter Shaw, MD, a pediatric hematologist/oncologist at Children's Hospital and the director of the hospital's Adolescent and Young Adult (AYA) Oncology Program.

"Research has shown that patients who are enrolled in clinical trials offering the most advanced cancer treatments do better than patients who receive conventional treatment," Dr. Shaw said. "Adolescents and young adults with cancer are less likely than younger children to be enrolled in clinical trials for two important reasons: the first factor is that AYA patients are frequently treated by adult oncologists at hospitals that aren't participating in clinical trials designed for cancers occurring in the pediatric and adolescent age groups. Our study demonstrated the second reason, which is that nationally, there are many more clinical trials available for the types of malignancies that most often occur in the younger patients

Drs. Shaw and study co-author A. Kim Ritchey, MD, chief of the Division of Pediatric Hematology/Oncology at Children's and vice chair of Clinical Affairs in the Department of Pediatrics, studied 640 new oncology patients treated at Children's between July 1, 2001, and June 30, 2006. The patients ranged in age from birth to 22 years old. The study found that:

  • 38 percent of patients younger than 15 were enrolled in a clinical trial.
  • 27 percent of AYA patients were enrolled in a clinical trial.
  • 41 percent of patients younger than 15 were not treated on a clinical trial because one was not available.
  • 57 percent of AYA patients were not treated on a clinical trial because one was not available.

"These findings underscore the need for AYA patients to be treated at centers such as children's hospitals that are involved in national cooperatives offering clinical trials of new treatments for pediatric and adolescent cancers," Dr. Ritchey said. "There also is a need for more national trials to be opened for AYA patients and the types of malignancies most common to them."

The national Children's Oncology Group -- of which Children's is a member -- has an AYA subcommittee on which Dr. Shaw serves that currently is evaluating the types of cancers affecting AYA patients and ways to increase clinical trials available to these patients, according to Drs. Shaw and Ritchey.

One strategy for ensuring that AYA patients are treated by oncologists who are most up-to-date on clinical trials and cutting-edge treatment programs is for pediatric oncology divisions to establish AYA oncology programs in cooperation with adult oncology counterparts.

The study is published in the December issue of the Journal of Pediatric Hematology/Oncology.


Story Source:

The above story is based on materials provided by Children's Hospital of Pittsburgh. Note: Materials may be edited for content and length.


Cite This Page:

Children's Hospital of Pittsburgh. "Cancer Study Finds Adolescents Don't Get Same Access To Latest Treatments As Younger Patients." ScienceDaily. ScienceDaily, 16 January 2008. <www.sciencedaily.com/releases/2008/01/080115132856.htm>.
Children's Hospital of Pittsburgh. (2008, January 16). Cancer Study Finds Adolescents Don't Get Same Access To Latest Treatments As Younger Patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/01/080115132856.htm
Children's Hospital of Pittsburgh. "Cancer Study Finds Adolescents Don't Get Same Access To Latest Treatments As Younger Patients." ScienceDaily. www.sciencedaily.com/releases/2008/01/080115132856.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins